↓ Skip to main content
What is this page? Embed badge

Treatment options in non-muscle-invasive bladder cancer after BCG failure

Overview of attention for article published in Indian Journal of Urology, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 508)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
126 news outlets
patent
1 patent

Readers on

mendeley
34 Mendeley
So far, Altmetric has seen 502 news stories from 126 outlets.
Nara Shimbun

イネレクスゾ承認。BCG不応の高リスク筋層非浸潤性膀胱がん治療を変える…

Nara Shimbun,

イネレクスゾ®、製造販売承認を取得 BCG療法後に残存・再発した上皮内がんを有する高リスク筋層非浸潤性膀胱がんの治療を 変える可能性をもつ、新たな選択肢 イネレクスゾ®は、抗がん剤（ゲムシタビン塩酸塩）を 膀胱内へ持続的に局所送達できる膀胱内投与用製剤です…

Hokkaido Shimbun Press

イネレクスゾ承認。BCG不応の高リスク筋層非浸潤性膀胱がん治療を変える新たな選択肢

Hokkaido Shimbun Press,

イネレクスゾ®、製造販売承認を取得 BCG療法後に残存・再発した上皮内がんを有する高リスク筋層非浸潤性膀胱がんの治療を 変える可能性をもつ、新たな選択肢 イネレクスゾ®は、抗がん剤（ゲムシタビン塩酸塩）を 膀胱内へ持続的に局所送達できる膀胱内投与用製剤です…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 498 additional news stories.